US Bancorp’s Kite Pharma, Inc. KITE Stock Holding History

US Bancorp’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-16	Closed	-$3K	–	3769
2017 Q3	$3K	Sell	16 -30	-65%	-$4.18K	﹤0.01%	3404
2017 Q2	$6K	Sell	46 -15	-25%	-$1.22K	﹤0.01%	3199
2017 Q1	$4K	Buy	61 +55	+917%	+$3.4K	﹤0.01%	3295
2016 Q4	$0	Buy	+6	New	+$294	﹤0.01%	3718
2016 Q3	–	Sell	-502	Closed	-$25K	–	3701
2016 Q2	$25K	Buy	502 +101	+25%	+$4.96K	﹤0.01%	2722
2016 Q1	$18K	Buy	+401	New	+$19.4K	﹤0.01%	2811
2015 Q3	–	Sell	-546	Closed	-$33K	–	3749
2015 Q2	$33K	Buy	+546	New	+$31.2K	﹤0.01%	2748

US Bancorp's KITE Position: Q4 2017 in Review

US Bancorp sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 16 shares — an estimated $3K sold.

US Bancorp first reported a position in KITE in Q2 2015 and held it in 7 quarters. The position peaked at $33K in Q2 2015. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

US Bancorp reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
US Bancorp sold 16 Kite Pharma, Inc. shares in Q4 2017, an estimated $3K.
US Bancorp first reported a position in Kite Pharma, Inc. in Q2 2015 and held it in 7 quarters.
US Bancorp's Kite Pharma, Inc. position peaked at $33K in Q2 2015.
0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on US Bancorp's 13F filing for Q4 2017, filed 2 Feb 2018.